A Study of Preferences for the First-Line Treatment of Advanced/Metastatic Non-Small Cell Lung Cancer

NCT05250817 | Completed

• 1 other identifier: CA209-69K
• Study Type: observational
• Target: 501
• Locations: 1 country
• Sites: 1

Brief Summary

The purpose of this observational study is to determine participants' preferences for outcomes associated with first-line treatment of advanced/metastatic Non-Small Cell Lung Cancer (NSCLC) using a discrete-choice experiment (DCE).

Conditions

Carcinoma, Non-Small-Cell Lung

Keywords

Preference; Advanced/Metastatic NSCLC; Discrete choice experiment (DCE)

Outcome Measures

Primary Outcomes (2)

• Set of relative preference weights for all attribute levels included in the Discrete Choice Experiment (DCE)

  At Baseline

• Respondents' baseline understanding of attribute descriptions

  At Baseline

Study Arms (2)

Cohort 1

Participants with early stage and advanced/metastatic non-small cell lung cancer (NSCLC)

Cohort 2

Participants from the general population

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

This observational study includes pretest interviews with 15 participants diagnosed with non-small cell lung cancer (NSCLC) and 15 participants selected from the general population following the study inclusion criteria. The final survey will be administered online to 150 participants with NSCLC and 500 participants from the general population.

You may qualify if:

• Participants:
• Must be 18 years of age or older
• Must be a US resident.
• Lung cancer participants with a physician diagnosis of NSCLC. Global Perspectives will be involved to suggest alternative strategies to a physician-confirmed diagnosis to ensure that actual cancer participants are recruited.

You may not qualify if:

• Not applicable

Sponsors & Collaborators

• Bristol-Myers Squibb: lead

Study Sites (1)

RTI Health Solutions

Research Triangle Park, North Carolina, 27709, United States

Location

Related Links

• BMS Clinical Trial Information
• Investigator Inquiry Form
• FDA Safety Alerts and Recalls

MeSH Terms

Conditions

Carcinoma, Non-Small-Cell Lung

Condition Hierarchy (Ancestors)

Carcinoma, Bronchogenic; Bronchial Neoplasms; Lung Neoplasms; Respiratory Tract Neoplasms; Thoracic Neoplasms; Neoplasms by Site; Neoplasms; Lung Diseases; Respiratory Tract Diseases

Study Officials

• Bristol-Myers Squibb

  Bristol-Myers Squibb

  STUDY DIRECTOR

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: February 11, 2022
• First Posted: February 22, 2022
• Study Start: December 9, 2021
• Primary Completion: January 4, 2023
• Study Completion: January 4, 2023
• Last Updated: June 9, 2023

Record last verified: 2023-06

Locations

US (1)